obesity-995x60.png
FEATURED ARTICLES
What Ecological Momentary Assessment Taught Us About Real-World Hearing Outcomes
Ecological momentary assessment (EMA) reveals how people experience hearing challenges beyond the clinic. Here, researchers highlight its relevance in designing real-world hearing studies.
-
![GettyImages-2257501711-lab-data-scientist-operations]( "Early-Phase Lab Data: Why It Breaks And How To Prevent Risk")
Early-Phase Lab Data: Why It Breaks And How To Prevent RiskLearn why lab data systems built quickly in early-phase trials tend to outlast their usefulness, quietly accumulating inconsistencies that surface only when scrutiny intensifies later in a study.
-
![CT scan heart]( "New Imaging Approach Could Improve IPF Trial Design")
New Imaging Approach Could Improve IPF Trial DesignAI-powered quantitative CT could help sponsors detect treatment effects earlier, strengthen IPF trial endpoints, and make better go/no-go decisions.
-
![African American Businessman-GettyImages-497984466]( "With CROs, Decide What You Can Actually Manage")
With CROs, Decide What You Can Actually ManageIndustry veteran Peter Fredette explores how small biotechs can rethink CRO outsourcing by balancing cost, operational needs, and internal oversight. Before choosing a CRO model, sponsors must honestly assess which services they need — and how many partners they can realistically manage.
SERVICES AND PRODUCTS
Explore the breadth of Altasciences’ expertise in clinical pharmacology studies, supporting regulatory submissions across a diverse range of therapeutic areas.
Managing clinical trial disclosure can be challenging with the ever-evolving regulatory landscape, and varying requirements across different jurisdictions and regulatory bodies. New and updated regulations need to be continuously monitored and assessed for potential impact on an organization, processes and overall strategy.
Ypsomed accelerates clinical progress by reducing barriers across clinical development, enabling earlier study readiness, greater visibility and more informed decisions.
Explore validated pain models and integrated early-phase services designed to characterize dose response, evaluate safety and efficacy, and support informed decisions in analgesic development.
DECODE, the Digital Endpoint Collaboration for Outcomes Development, is Ametris’ pre-competitive collaboration framework designed to help address shared clinical measurement challenges across the life sciences industry. In regulatory contexts where evidence expectations are high, digital measures must be meaningful to patients, scientifically valid, operationally feasible, and aligned with regulatory expectations. By supporting the development and validation of fit-for-purpose, patient-centered digital measures, DECODE helps transform real-world data into validated clinical evidence across clinical research programs.